Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Zanzalintinib”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 18 of 0 results

Early research (Phase 1)Looking for participantsNCT06952010
What this trial is testing

XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors

Who this might be right for
Solid TumorAdvanced Solid TumorMetastatic Solid Tumor+1 more
Exelixis 303
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07623460
What this trial is testing

Zanzalintinib Efficacy Post Pluvicto® in Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer

Who this might be right for
mCRPC (Metastatic Castration-resistant Prostate Cancer)
Stuthi Perimbeti 30
Large-scale testing (Phase 3)Looking for participantsNCT06943755
What this trial is testing

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

Who this might be right for
Pancreatic Neuroendocrine Tumor (pNET)Extra-Pancreatic Neuroendocrine Tumor (epNET)
Exelixis 440
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07714551
What this trial is testing

Zanzalintinib in Unresectable and Progressive MPGGs

Who this might be right for
PheochromocytomaParaganglioma
Dana-Farber Cancer Institute 14
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07226063
What this trial is testing

Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer

Who this might be right for
Hepatocellular CarcinomaLiver Cancer
Amit Mahipal 16
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07527169
What this trial is testing

Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory Neuroblastoma

Who this might be right for
Metastatic Olfactory Neuroblastoma
M.D. Anderson Cancer Center 16
Testing effectiveness (Phase 2)Looking for participantsNCT07043608
What this trial is testing

Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases

Who this might be right for
Clear Cell Renal Cell Cancer (ccRCC)Clear Cell Renal CarcinomaClear Cell Renal Cell Carcinoma Metastatic+7 more
Kelly Fitzgerald, MD 20
Early research (Phase 1)Looking for participantsNCT06795009
What this trial is testing

Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer

Who this might be right for
Uterine CancerEndometrial Cancer
Washington University School of Medicine 36
Testing effectiveness (Phase 2)Looking for participantsNCT06571734
What this trial is testing

XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma

Who this might be right for
Metastatic LeiomyosarcomaUnresectable LeiomyosarcomaBone Sarcoma+7 more
Northwestern University 73
Large-scale testing (Phase 3)Looking for participantsNCT07227402
What this trial is testing

A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

Who this might be right for
Renal Cell Carcinoma
Merck Sharp & Dohme LLC 904
Testing effectiveness (Phase 2)Looking for participantsNCT07283731
What this trial is testing

Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma

Who this might be right for
Phase 2ZanzalintinibPembrolizumab+2 more
M.D. Anderson Cancer Center 20
Large-scale testing (Phase 3)Active Not RecruitingNCT06082167
What this trial is testing

Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Who this might be right for
Head and Neck Squamous Cell Carcinoma
Exelixis 600
Testing effectiveness (Phase 2)Looking for participantsNCT06926634
What this trial is testing

Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)

Who this might be right for
High Grade Neuroendocrine Neoplasms
Washington University School of Medicine 32
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07511504
What this trial is testing

Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma

Who this might be right for
Locally Advanced Hepatocellular CarcinomaStage III Hepatocellular Carcinoma AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8+1 more
OHSU Knight Cancer Institute 40
Testing effectiveness (Phase 2)Looking for participantsNCT07428616
What this trial is testing

Zanzalintinib in Participants With Recurrent or Progressive Meningioma

Who this might be right for
Meningioma
Exelixis 100
Early research (Phase 1)Looking for participantsNCT06912087
What this trial is testing

Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC

Who this might be right for
Head and Neck NeoplasmsCarcinoma, Squamous CellNeoplasm Recurrence, Local+3 more
University of Chicago 36
Early research (Phase 1)Looking for participantsNCT05176483
What this trial is testing

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Who this might be right for
Renal Cell Carcinoma (RCC)Metastatic Castration-Resistant Prostate Cancer (mCRPC)Urothelial Carcinoma (UC)+8 more
Exelixis 1,394
Testing effectiveness (Phase 2)Looking for participantsNCT07218666
What this trial is testing

Zanzalintinib in Men With Aggressive Variant Prostate Cancer

Who this might be right for
Aggressive Variant Prostate Carcinoma
Deepak Kilari 30